{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:51:28Z","timestamp":1756572688820,"version":"3.37.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.14310\/horm.2002.1680","type":"journal-article","created":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T18:03:56Z","timestamp":1468087436000},"page":"368-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period"],"prefix":"10.1007","volume":"15","author":[{"given":"Olga","family":"Karapanou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella","family":"Tzanela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marietta","family":"Christoforaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lida","family":"Papastathopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Moutsatsou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efi","family":"Botoula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Tsagarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"15030368_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S, 2009 Acromegaly: pathogenesis and treatment. J Clin Invest 119: 3189\u20133202.","journal-title":"J Clin Invest"},{"key":"15030368_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.endonu.2012.09.010","volume":"60","author":"G Sesmilo","year":"2013","unstructured":"Sesmilo G, 2013 Epidemiology of acromegaly in Spain. Endocrinol Nutr 60: 470\u2013474.","journal-title":"Endocrinol Nutr"},{"key":"15030368_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"Fieffe S, Morange I, Petrossians P, et al, 2011 Diabetes in acromegaly, prevalence, risk factors and evolution: data from the French acromegaly registry. Eur J Endocrinol 164: 877\u2013884.","journal-title":"Eur J Endocrinol"},{"key":"15030368_CR4","first-page":"193","volume":"73","author":"P Petrossians","year":"2012","unstructured":"Petrossians P, Tichomirowa MA, Stevenaert A, Martion D, Daly AF, Beckers A, 2012 The liege acromegaly survey (LAS); a new software tool for the study of acromegaly. Ann Endocrinol Paris 73: 193\u2013201.","journal-title":"Ann Endocrinol Paris"},{"key":"15030368_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1023\/A:1009965803750","volume":"2","author":"IM Holdaway","year":"1999","unstructured":"Holdaway IM, Rajassorya C, 1999 Epidemiology of acromegaly. Pituitary 2: 29\u201341.","journal-title":"Pituitary"},{"key":"15030368_CR6","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A, 2006 High prevalence of pituitary adenomas: a cross-sectional study in the provence of Liege, Belgium. J Clin Endocrinol Metab 91: 4769\u20134775.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR7","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Raws ERJr, Melmed S, et al, 2014 Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 99: 3933\u20133951.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR8","first-page":"168","volume":"85","author":"MR Drange","year":"2000","unstructured":"Drange MR, Fram MR, Herman-Bonert V, Melmed S, 2000 Pituitary tumor registry: A novel clinical resource. J Clin Endocrinol Metab 85: 168\u2013174.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajassorya RC, Gamble GD, 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89: 667\u2013674.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR10","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1210\/jc.2004-1381","volume":"90","author":"R Kauppinen-M\u00e4kelin","year":"2005","unstructured":"Kauppinen-M\u00e4kelin R, Sane T, Reunanen A, et al, 2005 A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90: 4081\u20134086.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cen.12112","volume":"79","author":"S Vallette","year":"2013","unstructured":"Vallette S, Ezzat S, Chik C, et al, 2013 Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf) 79: 79\u201385.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"15030368_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","volume":"157","author":"M Bex","year":"2007","unstructured":"Bex M, Abs R, T\u2019Sjoen G, et al, 2007 AcroBel \u2014 the Belgian registry on acromegaly: a survey of the \u2018real-life\u2019 outcome in 418 acromegalic subjects. Eur J Endocrinol 157: 399\u2013409.","journal-title":"Eur J Endocrinol"},{"key":"15030368_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/EJE-12-0602","volume":"168","author":"C Schofl","year":"2012","unstructured":"Schofl C, Franz H, Grussendorf M, et al, 2012 Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol 168: 39\u201347.","journal-title":"Eur J Endocrinol"},{"key":"15030368_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/cen.12020","volume":"78","author":"O Kwon","year":"2013","unstructured":"Kwon O, Song YD, Kim SY, et al, 2013 Nationwide survey of acromegaly in South Korea. Clin Endocrinol (Oxf) 78: 577\u2013585.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"15030368_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1530\/EJE-12-0084","volume":"167","author":"M Arosio","year":"2012","unstructured":"Arosio M, Reimondo G, Malchiodi E, et al, 2012 Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167: 189\u2013198.","journal-title":"Eur J Endocrinol"},{"key":"15030368_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1530\/eje.0.1510439","volume":"151","author":"A Mestron","year":"2004","unstructured":"Mestron A, Webb SM, Astorga R, et al, 2004 Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol 151: 439\u2013446.","journal-title":"Eur J Endocrinol"},{"key":"15030368_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11102-012-0384-x","volume":"16","author":"G Sesmilo","year":"2013","unstructured":"Sesmilo G, Gaztambide S, Venegas E, et al, 2013 Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 16: 115\u2013121.","journal-title":"Pituitary"},{"key":"15030368_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1210\/jc.2014-2468","volume":"100","author":"D Cuevas-Ramos","year":"2015","unstructured":"Cuevas-Ramos D, Carmichael JD, Cooper O, et al, 2015 A structural and functional acromegaly classification. J Clin Endocrinol Metab 100: 122\u2013131.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jc.2011-0554","volume":"96","author":"JA Jane Jr","year":"2011","unstructured":"Jane Jr, JA, Starke RM, Elzoghby MA, et al, 2011 Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome. J Clin Endocrinol Metab 96: 1\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1530\/eje.0.1380160","volume":"138","author":"NC Thalassinos","year":"1998","unstructured":"Thalassinos NC, Tsagarakis S, Ioannides G, et al, 1998 Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrino 138: 160\u2013163.","journal-title":"Eur J Endocrino"},{"key":"15030368_CR21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jc.2005-1616","volume":"91","author":"PJ Jenkins","year":"2006","unstructured":"Jenkins PJ, Bates P, Carson MN, et al, 2006 Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91: 1239\u20131245.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR22","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1210\/jc.2014-2900","volume":"99","author":"AM Abu Dabrh","year":"2014","unstructured":"Abu Dabrh AM, Mohammed K, Asi N, et al, 2014 Surgical Interventions and Medical Treatments in Treatment-Na\u00efve Patients With Acromegaly: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 99: 4003\u20134014.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"Mercado M, Borges F, Bouterfa H, et al, 2007 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66: 659\u2013678.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"15030368_CR24","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"J Carmichael","year":"2014","unstructured":"Carmichael J, Bonert VS, Nuno M, et al, 2014 Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis. J Clin Endocrinol Metab 99: 1825\u20131833.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1210\/jc.2005-2347","volume":"91","author":"R Cozzi","year":"2006","unstructured":"Cozzi R, Montini M, Attanasio R, et al, 2006 Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91: 1397\u20131403.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR26","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1210\/jc.2003-030110","volume":"88","author":"R Cozzi","year":"2003","unstructured":"Cozzi R, Attanasio R, Montini M, et al, 2003 Four-Year Treatment with Octreotide-Long-Acting Repeatable in 110 Acromegalic Patients: Predictive Value of Short-Term Results by ROC analysis. J Clin Endocrinol Metab 88: 3090\u20133098.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR27","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1210\/jc.2014-2032","volume":"99","author":"SJ Neggers","year":"2014","unstructured":"Neggers SJ, Franck SE, de Rooij FW, et al, 2014 Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 99: 3644\u20133652.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2265.2008.03469.x","volume":"71","author":"CE Higham","year":"2009","unstructured":"Higham CE, Chung TT, Lawrance J, et al, 2009 Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 71: 86\u201391.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"15030368_CR29","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1210\/jc.2005-0260","volume":"90","author":"PU Freda","year":"2005","unstructured":"Freda PU, Katznelson L, van der Lely AJ, et al, 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90: 4465\u20134473.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR30","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1210\/jc.2004-1093","volume":"90","author":"JS Bevan","year":"2005","unstructured":"Bevan JS, 2005 Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90: 1856\u20131863.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR31","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1210\/jc.2006-2084","volume":"92","author":"E Resmini","year":"2007","unstructured":"Resmini E, Dadati P, Ravetti JL, et al, 2007 Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92: 1592\u20131599.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR32","doi-asserted-by":"publisher","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, et al, 2012 Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 7: e36411.","journal-title":"PLoS One"},{"key":"15030368_CR33","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, et al, 2014 Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial. J Clin Endocrinol Metab 99: 1282\u20131290.","journal-title":"J Clin Endocrinol Metab"},{"key":"15030368_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.0300-0664.2001.01438.x","volume":"56","author":"G Amato","year":"2002","unstructured":"Amato G, Mazziotti G, Rotondi M, et al, 2002 Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56: 65\u201371.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"15030368_CR35","first-page":"1416","volume":"79","author":"U Pl\u00f6ckinger","year":"1994","unstructured":"Pl\u00f6ckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ, 1994 Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79: 1416\u20131423.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1680\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:39:18Z","timestamp":1739115558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["15030368"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1680","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"type":"print","value":"1109-3099"},{"type":"electronic","value":"2520-8721"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"16 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}